Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Nov 7, 2006

Medarex and PacMab to Develop Therapeutic Antibodies for Blood Cancer

  • Medarex and PacMab will develop Mab-based therapies for blood cancers, under a collaborative agreement between the two firms. "Initially we will focus on the most prevalent form of multiple myeloma,” says Alan Liddle, CEO of PacMab. “At the same time, we will be developing our pipeline of additional drug therapies using our monoclonal antibody technology aimed at other blood disorders with unmet clinical needs."

    The companies plan to begin clinical trials for PacMab’s existing antibody therapeutic in 2007. Through a collaborative development program, the companies intend to use Medarex' UltiMAb Human Antibody Development System® to generate fully human antibodies for novel disease targets.

    Under the terms of the agreement, Medarex and PacMab will share product development and commercialization responsibilities on any antibody products resulting from this collaboration.



Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »